title: The placenta in toxicology. Part IV: Battery of toxicological test systems based on human placenta.
abstract: This review summarizes the potential and also some limitations of using human placentas, or placental cells and structures for toxicology testing. The placenta contains a wide spectrum of cell types and tissues, such as trophoblast cells, immune cells, fibroblasts, stem cells, endothelial cells, vessels, glands, membranes, and many others. It may be expected that in many cases the relevance of results obtained from human placenta will be higher than those from animal models due to species specificity of metabolism and placental structure. For practical and economical reasons, we propose to apply a battery of sequential experiments for analysis of potential toxicants. This should start with using cell lines, followed by testing placenta tissue explants and isolated placenta cells, and finally by application of single and dual side ex vivo placenta perfusion. With each of these steps, the relative workload increases while the number of feasible repeats decreases. Simultaneously, the predictive power enhances by increasing similarity with in vivo human conditions. Toxic effects may be detected by performing proliferation, vitality and cell death assays, analysis of protein and hormone expression, immunohistochemistry or testing functionality of signaling pathways, gene expression, transport mechanisms, and so on. When toxic effects appear at any step, the subsequent assays may be cancelled. Such a system may be useful to reduce costs and increase specificity in testing questionable toxicants. Nonetheless, it requires further standardization and end point definitions for better comparability of results from different toxicants and to estimate the respective in vivo translatability and predictive value.
authors.affiliation: 1Placenta-Labor, Department of Obstetrics, University Hospital, Jena, Germany.
authors.forename: Claudia
authors.initials: C
authors.lastname: Göhner
authors.forename: Judit
authors.initials: J
authors.lastname: Svensson-Arvelund
authors.forename: Christiane
authors.initials: C
authors.lastname: Pfarrer
authors.forename: Jan-Dirk
authors.initials: JD
authors.lastname: Häger
authors.forename: Marijke
authors.initials: M
authors.lastname: Faas
authors.forename: Jan
authors.initials: J
authors.lastname: Ernerudh
authors.forename: J Mark
authors.initials: JM
authors.lastname: Cline
authors.forename: Darlene
authors.initials: D
authors.lastname: Dixon
authors.forename: Eberhard
authors.initials: E
authors.lastname: Buse
authors.forename: Udo R
authors.initials: UR
authors.lastname: Markert
mesh_terms: D005260:Female; D006801:Humans; D010920:Placenta / Q000166:cytology* / Q000187:drug effects*; D011247:Pregnancy; D018675:Toxicity Tests / Q000379:methods*
keywords: choriocarcinoma; human toxicology.; placenta; placenta explant; placenta perfusion; trophoblast
references.citation: Am J Obstet Gynecol. 1972 Nov 15;114(6):822-8
references.pmid: 4676572
references.citation: Reprod Biol Endocrinol. 2004 Jul 05;2:46
references.pmid: 15236656
references.citation: Toxicology. 2006 Nov 10;228(1):98-108
references.pmid: 16996190
references.citation: Placenta. 2001 Feb-Mar;22(2-3):251-5
references.pmid: 11170831
references.citation: Am J Reprod Immunol. 2009 Jan;61(1):19-25
references.pmid: 19086988
references.citation: Curr Protoc Immunol. 2012 Apr;Chapter 7:Unit 7.40.1-11
references.pmid: 22470137
references.citation: Exp Cell Res. 1993 Jun;206(2):204-11
references.pmid: 7684692
references.citation: Br J Pharmacol. 2009 Oct;158(3):665-78
references.pmid: 19788499
references.citation: Arch Gynecol Obstet. 2012 Jan;285(1):7-14
references.pmid: 21431844
references.citation: Expert Opin Drug Metab Toxicol. 2012 Oct;8(10):1263-75
references.pmid: 22780574
references.citation: Reprod Toxicol. 1992;6(1):69-75
references.pmid: 1562801
references.citation: BMC Dev Biol. 2007 Dec 19;7:137
references.pmid: 18093301
references.citation: Toxicol Lett. 2012 Jan 5;208(1):92-9
references.pmid: 22037670
references.citation: BMC Cancer. 2010 Oct 13;10:553
references.pmid: 20942921
references.citation: Microvasc Res. 2012 Jul;84(1):65-73
references.pmid: 22480576
references.citation: Methods Mol Biol. 2012;817:55-67
references.pmid: 22147568
references.citation: J Toxicol Environ Health. 1984;14(2-3):419-32
references.pmid: 6502743
references.citation: Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):29-33
references.pmid: 17350747
references.citation: Hum Exp Toxicol. 1998 Mar;17(3):176-81
references.pmid: 9587787
references.citation: Toxicol Lett. 2009 Sep 28;189(3):248-52
references.pmid: 19539015
references.citation: Zentralbl Gynakol. 1990;112(4):207-14
references.pmid: 2336893
references.citation: Zentralbl Gynakol. 1982;104(18):1149-54
references.pmid: 7158136
references.citation: Immunogenetics. 2006 Jan;57(12):904-16
references.pmid: 16391939
references.citation: Clin Exp Pharmacol Physiol. 1988 Nov;15(11):837-44
references.pmid: 3229008
references.citation: Curr Pharm Biotechnol. 2011 May;12(5):804-13
references.pmid: 21480826
references.citation: Toxicol Pathol. 2014;42(2):339-44
references.pmid: 23531795
references.citation: Birth Defects Res C Embryo Today. 2004 Dec;72(4):345-60
references.pmid: 15662707
references.citation: Toxicol Appl Pharmacol. 2012 Mar 15;259(3):366-75
references.pmid: 22310176
references.citation: Expert Rev Clin Immunol. 2011 Sep;7(5):603-9
references.pmid: 21895473
references.citation: Placenta. 2012 Jan;33(1):60-6
references.pmid: 22082655
references.citation: Placenta. 2005 Jul;26(6):439-48
references.pmid: 15950058
references.citation: Curr Opin Pediatr. 2010 Apr;22(2):208-18
references.pmid: 20216314
references.citation: Placenta. 2010 Aug;31(8):686-90
references.pmid: 20553811
references.citation: Placenta. 2010 Nov;31(11):989-96
references.pmid: 20850871
references.citation: Am J Pathol. 2011 Jun;178(6):2792-801
references.pmid: 21641401
references.citation: Am J Reprod Immunol. 2010 Jun;63(6):492-505
references.pmid: 20236263
references.citation: Mol Hum Reprod. 2010 May;16(5):361-72
references.pmid: 20083559
references.citation: Toxicol Sci. 2006 Sep;93(1):75-81
references.pmid: 16790488
references.citation: Toxicol In Vitro. 2010 Sep;24(6):1532-7
references.pmid: 20624455
references.citation: Reprod Toxicol. 2010 Aug;30(1):131-7
references.pmid: 20214975
references.citation: Leuk Lymphoma. 2013 Aug;54(8):1811-3
references.pmid: 23240910
references.citation: Placenta. 2011 Oct;32(10):788-92
references.pmid: 21821285
references.citation: Infect Dis Obstet Gynecol. 2008;2008:927574
references.pmid: 18551180
references.citation: Leukemia. 1994 Apr;8(4):652-8
references.pmid: 8152260
references.citation: J Clin Invest. 1958 Nov;37(11):1516-23
references.pmid: 13587660
references.citation: Toxicol In Vitro. 2012 Apr;26(3):406-13
references.pmid: 22265773
references.citation: Placenta. 2012 Sep;33(9):725-34
references.pmid: 22721760
references.citation: Placenta. 2012 May;33(5):433-9
references.pmid: 22374511
references.citation: Clin Pharmacol Ther. 2011 Jul;90(1):67-76
references.pmid: 21562489
references.citation: Z Gesamte Exp Med. 1960;132:577-84
references.pmid: 14443288
references.citation: J Clin Endocrinol Metab. 1981 Mar;52(3):447-50
references.pmid: 6970203
references.citation: Chemosphere. 2006 Jan;62(4):573-80
references.pmid: 16122778
references.citation: Placenta. 2010 Oct;31(10):848-52
references.pmid: 20708796
references.citation: Am J Obstet Gynecol. 1993 May;168(5):1587-97
references.pmid: 8498447
references.citation: Immunobiology. 2004;209(7):569-74
references.pmid: 15568621
references.citation: Mol Hum Reprod. 2000 Jul;6(7):635-41
references.pmid: 10871651
references.citation: Environ Res. 2000 May;83(1):54-66
references.pmid: 10845782
references.citation: Alcohol Clin Exp Res. 1994 Dec;18(6):1448-55
references.pmid: 7695043